Nā mea nui no nā mākua a me nā kahu hānai:

• Pono: Ua hoʻohālikelike ʻia nā pane o nā keiki 5 a hiki i ka 11 makahiki me ko nā kānaka 16 a hiki i ka 25 makahiki. I loko o kēlā noiʻi ʻana, he 90.7% ka hopena o ke kano i ka pale ʻana i ka COVID-19 i nā keiki 5 a hiki i 11.

• Palekana: Ua aʻo ʻia ka palekana o ka lāʻau lapaʻau ma kahi o 3,100 mau keiki mai ka makahiki 5 a hiki i ka makahiki 11 i loaʻa i ka lāʻau lapaʻau a ʻaʻohe hopena koʻikoʻi i ʻike ʻia ma ke aʻo ʻana.

• E hui ana ka Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices i kēia pule aʻe no ke kūkākūkā ʻana i nā ʻōlelo aʻo hou aʻe.

"Ma ke ʻano he makuahine a he kauka, ʻike wau ua kali nā mākua, nā kahu mālama, nā limahana kula, a me nā keiki i ka mana o kēia lā. ʻO ka hoʻopaʻa ʻana i nā keiki liʻiliʻi e kūʻē iā COVID-19 e hoʻokokoke iā mākou i ka hoʻi ʻana i ke ʻano o ka maʻamau, "wahi a Acting FDA Commissioner Janet Woodcock, MD "ʻO kā mākou loiloi piha a paʻa i ka ʻikepili e pili ana i ka palekana a me ka pono o ka lāʻau lapaʻau e kōkua i ka hōʻoia ʻana i nā mākua a me nā kahu. i kūpono kēia kano i kā mākou kūlana kiʻekiʻe. "

Hāʻawi ʻia ka Pfizer-BioNTech COVID-19 Vaccine no nā keiki 5 a hiki i ka 11 mau makahiki ma ke ʻano he ʻelua ʻano kumu mua, 3 mau pule ma kahi kaʻawale, akā he haʻahaʻa haʻahaʻa (10 micrograms) ma mua o ka mea i hoʻohana ʻia no nā poʻe 12 makahiki a ʻoi aku. (30 micrograms).

Ma US, ʻo nā hihia COVID-19 i nā keiki 5 a hiki i 11 mau makahiki he 39% o nā hihia i nā poʻe ʻōpio ma mua o 18 mau makahiki. Wahi a ka CDC, ma kahi o 8,300 mau hihia COVID-19 i nā keiki 5 a hiki i 11 mau makahiki i hopena i ka haukapila. Ma ʻOkakopa 17, ua hōʻike ʻia he 691 mau make mai COVID-19 ma US i nā poʻe ma lalo o 18 mau makahiki, me 146 mau make ma ka hui 5 a 11 mau makahiki.

"Ua kūpaʻa ka FDA i ka hoʻoholo ʻana i alakaʻi ʻia e ka ʻepekema i hiki i ka lehulehu a me ke kaiāulu mālama ola ke hilinaʻi. Manaʻo mākou i ka palekana, ka pono a me ka ʻikepili hana ma hope o kēia ʻae. Ma ke ʻano o ko mākou kūpaʻa ʻana i ka ʻike maopopo e pili ana i kā mākou hoʻoholo ʻana, ʻo ia hoʻi ka hui ʻana o kā mākou komite aʻoaʻo lehulehu ma mua o kēia pule, ua kau mākou i nā palapala i kēia lā e kākoʻo ana i kā mākou hoʻoholo a e hoʻopuka koke ʻia nā ʻike hou e pili ana i kā mākou loiloi i ka ʻikepili. Manaʻo mākou e kōkua kēia ʻike i ke kūkulu ʻana i ka hilinaʻi o nā mākua e hoʻoholo nei inā e hana ʻia kā lākou mau keiki i ke kano," wahi a Peter Marks, MD, Ph.D., ka luna o ka FDA's Center for Biologics Evaluation and Research.

Ua hoʻoholo ka FDA ua hoʻokō kēia kano Pfizer i nā koina no ka ʻae ʻana i ka hoʻohana pilikia. Ma muli o ka nui o nā hōʻike ʻepekema i loaʻa, ʻoi aku ka nui o nā pono i ʻike ʻia a hiki i ka Pfizer-BioNTech COVID-19 i nā poʻe a hiki i ka 5 mau makahiki ma mua o ka ʻike a me nā pilikia.

He aha e lawe ʻia mai kēia ʻatikala:

Hāʻawi ʻia ka Pfizer-BioNTech COVID-19 Vaccine no nā keiki 5 a hiki i ka 11 mau makahiki ma ke ʻano he ʻelua ʻano kumu mua, 3 mau pule ma kahi kaʻawale, akā he haʻahaʻa haʻahaʻa (10 micrograms) ma mua o ka mea i hoʻohana ʻia no nā poʻe 12 makahiki a ʻoi aku. (30 micrograms).
Based on the totality of scientific evidence available, the known and potential benefits of the Pfizer-BioNTech COVID-19 vaccine in individuals down to 5 years of age outweigh the known and potential risks.
The vaccine’s safety was studied in approximately 3,100 children age 5 through 11 who received the vaccine and no serious side effects have been detected in the ongoing study.